MAGEA1 Antibody (MZ2E/838), Novus Biologicals™

MAGE 1

0.2mg/mL

Flow Cytometry, Immunohistochemistry (Paraffin), Immunofluorescence

Unconjugated

Mouse

Apoptosis, Cancer, Melanoma Cell Markers, Tumor Suppressors

10mM PBS and 0.05% BSA with 0.05% Sodium Azide

4100

Recombinant human MAGEA1 protein

Primary

Store at 4C.

MZ2E/838

Flow Cytometry 0.5 - 1 ug/million cells in 0.1 ml, Immunohistochemistry-Paraffin 0.5 - 1.0 ug/ml, Immunofluorescence 1 - 2 ug/ml

Monoclonal

Purified

RUO

Human

Antigen MZ2-E, Cancer/testis antigen 1.1, cancer/testis antigen family 1, member 1, CT1.1melanoma antigen family A 1, MAGE-1 antigen, MAGE1A, MAGE1melanoma antigen MAGE-1, melanoma antigen family A, 1 (directs expression of antigen MZ2-E), melanoma-associated antigen 1, melanoma-associated antigen MZ2-E, MGC9326

MAGEA1

IgG1 κ

Protein A or G purified

Recognizes a protein of 42-46kDa, identified as MAGE-1. This MAb does not cross-react with other members of MAGE-family. Human malignant neoplasms carry rejection antigens that are recognized by the patients' autologous, tumor directed and specific, cytolytic, CD8+ T lymphocyte clones (CTL). The MAGE family of genes codes an important group of antigens. It was identified that melanomas and primary glial brain tumors express common melanoma associated antigens (MAAs). Because MAGE-1 is expressed on a significant proportion of human neoplasms of various histological types (melanoma, brain tumors of glial origin, neuroblastoma, non-small cell lung cancer, breast, gastric, colorectal, ovarian, renal cell carcinomas) and not on normal tissues, the encoded antigen may serve as a marker of early detection and target for cancer immunotherapy.